Safety and tolerability of single-agent belantamab mafodotin (Belamaf; GSK2857916) in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM): Pooled data from DREAMM-1 and DREAMM-2

被引：0
|
作者：
Kortuem, M. [1 ]
Trudel, S. [2 ]
Cohen, A. D. [3 ]
Richardson, P. G. [4 ]
Lonial, S. [5 ]
Opalinska, J. B. [6 ]
Gupta, I [6 ]
Byrne, J. [6 ]
Zhi, E. [6 ]
Baron, J. [6 ]
Morgan, L. [6 ]
Voorhees, P. M. [7 ]
Popat, R. [8 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin 2, Wurzburg, Germany
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] GlaxoSmithKline, Upper Providence, PA USA
[7] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[8] NHS Fdn Trust, Univ Coll London Hosp, London, England
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷 / SUPPL 4期
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
203
引用
收藏
页码：97 / 98
页数：2
相关论文
共 50 条
  • [1] DREAMM-2: Single-agent belantamab mafodotin (belamaf; GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) - outcomes by prior therapies
    Weisel, K.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Vorhees, P.
    Opalinska, J.
    Hoos, A.
    Zhi, E.
    Baron, J.
    Piontek, T.
    Jewell, R.
    Gupta, I
    Cohen, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 109 - 110
  • [2] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment
    Kortuem, M.
    Lee, H. C.
    Cohen, A. D.
    Chari, A.
    Hultcrantz, M.
    Nooka, A. K.
    Callander, N.
    Suvannasankha, A.
    Badros, A.
    Libby, E.
    Trudel, S.
    Richardson, P.
    Sborov, D.
    Rodriguez Otero, P.
    Lonial, S.
    Zhi, E.
    Lewis, E.
    Gupta, I
    Opalinska, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 102 - 102
  • [3] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and renal impairment.
    Lee, Hans Chulhee
    Cohen, Adam D.
    Chari, Ajai
    Hultcrantz, Malin
    Nooka, Ajay K.
    Callander, Natalie Scott
    Suvannasankha, Attaya
    Badros, Ashraf
    Libby, Edward N.
    Trudel, Suzanne
    Richardson, Paul G.
    Sborov, Douglas Weston
    Rodriguez Otero, Paula
    Lonial, Sagar
    Zhi, Eric
    Lewis, Eric
    Gupta, Ira
    Opalinska, Joanna
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and High-Risk (HR) cytogenetics
    Besemer, B.
    Cohen, A. D.
    Trudel, S.
    Lonial, S.
    Libby, E.
    Lee, H. C.
    Facon, T.
    Nooka, A. K.
    Callander, N.
    Chari, A.
    Gupta, I
    Paul, S.
    Opalinska, J.
    Richardson, P.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 98 - 98
  • [5] DREAMM-2: Single-agent belantamab mafodotin (GSK2857916) in patients with relapsed/refractory multiple myeloma (RRMM) and high-risk (HR) cytogenetics.
    Cohen, Adam D.
    Trudel, Suzanne
    Lonial, Sagar
    Libby, Edward N.
    Lee, Hans Chulhee
    Besemer, Britta
    Facon, Thierry
    Nooka, Ajay K.
    Callander, Natalie Scott
    Chari, Ajai
    Gupta, Ira
    Paul, Sofia
    Opalinska, Joanna
    Richardson, Paul G.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Assessing Efficacy via Indirect Comparison of Single-Agent Belantamab Mafodotin (Belamaf; GSK2857916) in DREAMM-2 Versus STORM or MAMMOTH Studies in Relapsed/Refractory Multiple Myeloma (RRMM)
    Suvannasankha, Attaya
    Kapetanakis, Venediktos
    Prawitz, Thibaud
    Sarri, Grammati
    Hughes, Rachel
    Wang, Feng
    Hogea, Cosmina
    Ferrante, Shannon Allen
    Gorsh, Boris
    Willson, Jenny
    Popat, Rakesh
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S300 - S301
  • [7] DREAMM-2: Belantamab mafodotin (belamaf; GSK2857916) effect on disease symptoms and health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM)
    Weisel, K.
    Popat, R.
    Lonial, S.
    Lee, H.
    Badros, A.
    Trudel, S.
    Nooka, A.
    Chari, A.
    Abdallah, A-O
    Callander, N.
    Sborov, D.
    Suvannasankha, A.
    Voorhees, P.
    Cohen, A.
    Opalinska, J.
    Gutierrez, B.
    Gorsh, B.
    He, Z.
    Eliason, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 103 - 104
  • [8] Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
    Nooka, Ajay
    Lee, Hans C.
    Badros, Ashraf Z.
    Voorhees, Peter
    Hultcrantz, Malin
    Karlin, Lionel
    Arnulf, Bertrand
    Richardson, Paul G.
    Zhi, Eric
    Baron, January
    Piontek, Trisha
    Lewis, Eric
    Opalinska, Joanna
    Gupta, Ira
    Cohen, Adam D.
    Lonial, Sagar
    BLOOD, 2020, 136
  • [9] Ocular Health of Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Data from the DREAMM-2 Trial of Belantamab Mafodotin (Belamaf)
    Popat, Rakesh
    Kazantzi, Aikaterini
    Farooq, Asim
    Thulasi, Praneetha
    Lonial, Sagar
    Jakubowiak, Andrzej
    Badros, Ashraf Z.
    Jeng, Bennie H.
    Opalinska, Joanna
    Baron, January
    Piontek, Trisha
    Byrne, Julie
    Womersley, Lynsey
    Gupta, Ira
    Esposti, Simona Degli
    BLOOD, 2020, 136
  • [10] Belantamab Mafodotin (Belamaf; GSK2857916) US Expanded Access Program (EAP) for Heavily Pre-Treated Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Baseline Characteristics
    Hultcrantz, Malin
    Anderson, Larry D., Jr.
    Anwer, Faiz
    Gasparetto, Cristina
    Kocoglu, Mehmet H.
    Lichtman, Eben I.
    Mo, Clifton
    Niesvizky, Ruben
    Lewis, Eric
    Li, Hong
    Paul, Sofia
    Petrone, Stephanie
    Kaufman, Jonathan L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S439 - S440
12345